Literature DB >> 25625806

Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines).

Norihiro Kokudo1, Kiyoshi Hasegawa, Masaaki Akahane, Hiroshi Igaki, Namiki Izumi, Takafumi Ichida, Shinji Uemoto, Shuichi Kaneko, Seiji Kawasaki, Yonson Ku, Masatoshi Kudo, Shoji Kubo, Tadatoshi Takayama, Ryosuke Tateishi, Takashi Fukuda, Osamu Matsui, Yutaka Matsuyama, Takamichi Murakami, Shigeki Arii, Masatoshi Okazaki, Masatoshi Makuuchi.   

Abstract

The 3rd version of Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine, which was published in October 2013 in Japanese. Here, we briefly describe new or changed recommendations with a special reference to the two algorithms for surveillance, diagnosis, and treatment.
© 2015 The Japan Society of Hepatology.

Entities:  

Keywords:  algorithm for surveillance and diagnosis; algorithm for treatment; clinical practice guidelines; clinical question; evidence-based medicine

Year:  2015        PMID: 25625806     DOI: 10.1111/hepr.12464

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  132 in total

Review 1.  Management before hepatectomy for hepatocellular carcinoma with cirrhosis.

Authors:  Hisashi Nakayama; Tadatoshi Takayama
Journal:  World J Hepatol       Date:  2015-09-18

2.  Prognostic Significance of Treatment Strategies for the Recurrent Hepatocellular Carcinomas After Radical Resection.

Authors:  Ryo Saito; Hidetake Amemiya; Naohiro Hosomura; Hiromichi Kawaida; Suguru Maruyama; Hiroki Shimizu; Shinji Furuya; Hidenori Akaike; Yoshihiko Kawaguchi; Makoto Sudo; Shingo Inoue; Hiroshi Kono; Daiduke Ichikawa
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

3.  Should AFP (or any biomarkers) be used for HCC surveillance?

Authors:  Hager F Ahmed Mohammed; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2017-04-28

4.  Liver Transplantation for Intermediate-Stage Hepatocellular Carcinoma.

Authors:  Naoko Kamo; Toshimi Kaido; Shintaro Yagi; Hideaki Okajima; Shinji Uemoto
Journal:  Liver Cancer       Date:  2018-03-01       Impact factor: 11.740

5.  Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe.

Authors: 
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

6.  Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2017-03-09       Impact factor: 11.740

Review 7.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

8.  Management of Hepatocellular Carcinoma in Japan as a World-Leading Model.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2017-12-13       Impact factor: 11.740

9.  Inspiration of liver resection for hepatocellular carcinoma associated with hepatic vein invasion, not inferior vena cava invasion.

Authors:  Nam-Joon Yi
Journal:  Hepatobiliary Surg Nutr       Date:  2018-10       Impact factor: 7.293

10.  Stereotactically navigated percutaneous microwave ablation (MWA) compared to conventional MWA: a matched pair analysis.

Authors:  L P Beyer; L Lürken; N Verloh; M Haimerl; K Michalik; J Schaible; C Stroszczynski; P Wiggermann
Journal:  Int J Comput Assist Radiol Surg       Date:  2018-05-04       Impact factor: 2.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.